TARPLIN, DOWNS & YOUNG, LLC

Lobbying for AMGEN INC

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 16, 2025

Lobbying activity 3

Health Issues

IRA, 340B, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency

Medicare/Medicaid

Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, 340B

Budget/Appropriations

federal budget issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.